Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, will be participating in the H.C. Wainwright Bioconnect Conference; the multiday conference is scheduled for Jan. 10–13, 2022. According to the announcement, MINDCURE president and CEO Kelsey Ramsden will provide a virtual presentation, which will be available for viewing beginning on Monday, Jan. 10, 2022, at 7 a.m. ET; the presentation will be available for 90 days. Ramsden will also be available for one-on-one meetings. The announcement also noted that MINDCURE has granted a total of 350,000 stock options to specific employees and consultants in accordance with terms outlined in the company’s long-term incentive plan. Those stock options are subject to the terms of the plan.
To view the presentation, visit https://ibn.fm/aZ09M
To view the full press release, visit https://ibn.fm/HkMXQ
About Mind Cure Health Inc.
MINDCURE is a life-sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
